About Enhancer
| Enhancer ID: | E_02_0785 |
| Species: | human |
| Position : | chr12:56330413-56330909   |
| Biosample name: | |
| Experiment class : | Low+High throughput |
| Enhancer type: | Enhancer |
| Disease: | Fibrotic disease |
| Pubmed ID: | 28916223 |
| Enhancer experiment: | ChIP-seq,PCR,ChIP |
| Enhancer experiment description: | Analysis of publicly available data from the ENCODE project [18] (Fig. 1A), as well as our own ChIP experiments [8] revealed that the DGKA DMR carries H3K27ac. ChIP showed that JQ1 reduced the deposition of H3K27ac levels specifically at the DGKA enhancer site(DMR), but did not affect the upstream DGKA promoter sites 1 and 2 (Fig. 2C). |
About Target gene
| Target gene : | DGKA(DAGK,DAGK1,DGK-alpha),DGKA(DAGK,DAGK1,DGK-alpha),DGKA(DAGK,DAGK1,DGK-alpha),DGKA(DAGK,DAGK1,DGK-alpha),DGKA(DAGK,DAGK1,DGK-alpha),DGKA(DAGK,DAGK1,DGK-alpha),DGKA(DAGK,DAGK1,DGK-alpha) |
| Strong evidence: | -- |
| Less strong evidence: | ChIP,PCR |
| Target gene experiment description: | From various NHDFs,we selected three fibroblast lines (data not shown) with significant differences in DGKA DNA methylation at the DGKA enhancer site(Fig. 1A) and inducible DGKA mRNA expression (Fig. 1B). Increased DNA methylation at the DGKA enhancer was associated with a lack of DGKA induction after exposure to bleomycin (Fig. 1B, Fibroblast3), confirming our previous findings in numerous patient-derived NHDF.EGR1 was significantly induced in two NHDF showing high DGKA induction (Fig. 1C).;From various NHDFs,we selected three fibroblast lines (data not shown) with significant differences in DGKA DNA methylation at the DGKA enhancer site(Fig. 1A) and inducible DGKA mRNA expression (Fig. 1B). Increased DNA methylation at the DGKA enhancer was associated with a lack of DGKA induction after exposure to bleomycin (Fig. 1B, Fibroblast3), confirming our previous findings in numerous patient-derived NHDF.EGR1 was significantly induced in two NHDF showing high DGKA induction (Fig. 1C).;From various NHDFs,we selected three fibroblast lines (data not shown) with significant differences in DGKA DNA methylation at the DGKA enhancer site(Fig. 1A) and inducible DGKA mRNA expression (Fig. 1B). Increased DNA methylation at the DGKA enhancer was associated with a lack of DGKA induction after exposure to bleomycin (Fig. 1B, Fibroblast3), confirming our previous findings in numerous patient-derived NHDF.EGR1 was significantly induced in two NHDF showing high DGKA induction (Fig. 1C).;From various NHDFs,we selected three fibroblast lines (data not shown) with significant differences in DGKA DNA methylation at the DGKA enhancer site(Fig. 1A) and inducible DGKA mRNA expression (Fig. 1B). Increased DNA methylation at the DGKA enhancer was associated with a lack of DGKA induction after exposure to bleomycin (Fig. 1B, Fibroblast3), confirming our previous findings in numerous patient-derived NHDF.EGR1 was significantly induced in two NHDF showing high DGKA induction (Fig. 1C).;From various NHDFs,we selected three fibroblast lines (data not shown) with significant differences in DGKA DNA methylation at the DGKA enhancer site(Fig. 1A) and inducible DGKA mRNA expression (Fig. 1B). Increased DNA methylation at the DGKA enhancer was associated with a lack of DGKA induction after exposure to bleomycin (Fig. 1B, Fibroblast3), confirming our previous findings in numerous patient-derived NHDF.EGR1 was significantly induced in two NHDF showing high DGKA induction (Fig. 1C).;From various NHDFs,we selected three fibroblast lines (data not shown) with significant differences in DGKA DNA methylation at the DGKA enhancer site(Fig. 1A) and inducible DGKA mRNA expression (Fig. 1B). Increased DNA methylation at the DGKA enhancer was associated with a lack of DGKA induction after exposure to bleomycin (Fig. 1B, Fibroblast3), confirming our previous findings in numerous patient-derived NHDF.EGR1 was significantly induced in two NHDF showing high DGKA induction (Fig. 1C).;From various NHDFs,we selected three fibroblast lines (data not shown) with significant differences in DGKA DNA methylation at the DGKA enhancer site(Fig. 1A) and inducible DGKA mRNA expression (Fig. 1B). Increased DNA methylation at the DGKA enhancer was associated with a lack of DGKA induction after exposure to bleomycin (Fig. 1B, Fibroblast3), confirming our previous findings in numerous patient-derived NHDF.EGR1 was significantly induced in two NHDF showing high DGKA induction (Fig. 1C). |
About TF
| TF name : | EGR1(AT225,G0S30,KROX-24,NGFI-A,TIS8,ZIF-268,ZNF225)EGR1(AT225,G0S30,KROX-24,NGFI-A,TIS8,ZIF-268,ZNF225)EGR1(AT225,G0S30,KROX-24,NGFI-A,TIS8,ZIF-268,ZNF225)EGR1(AT225,G0S30,KROX-24,NGFI-A,TIS8,ZIF-268,ZNF225)EGR1(AT225,G0S30,KROX-24,NGFI-A,TIS8,ZIF-268,ZNF225)EGR1(AT225,G0S30,KROX-24,NGFI-A,TIS8,ZIF-268,ZNF225)EGR1(AT225,G0S30,KROX-24,NGFI-A,TIS8,ZIF-268,ZNF225) |
| TF experiment: | qPCR |
| TF experiment description: | Relative DGKA (B) and EGR1 (C) mRNA expression levels in three individual NHDF exposed to bleomycin (40 mM) or vehicle control (DMSO) for 48 h. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001, n.s. not significant.;Relative DGKA (B) and EGR1 (C) mRNA expression levels in three individual NHDF exposed to bleomycin (40 mM) or vehicle control (DMSO) for 48 h. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001, n.s. not significant.;Relative DGKA (B) and EGR1 (C) mRNA expression levels in three individual NHDF exposed to bleomycin (40 mM) or vehicle control (DMSO) for 48 h. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001, n.s. not significant.;Relative DGKA (B) and EGR1 (C) mRNA expression levels in three individual NHDF exposed to bleomycin (40 mM) or vehicle control (DMSO) for 48 h. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001, n.s. not significant.;Relative DGKA (B) and EGR1 (C) mRNA expression levels in three individual NHDF exposed to bleomycin (40 mM) or vehicle control (DMSO) for 48 h. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001, n.s. not significant.;Relative DGKA (B) and EGR1 (C) mRNA expression levels in three individual NHDF exposed to bleomycin (40 mM) or vehicle control (DMSO) for 48 h. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001, n.s. not significant.;Relative DGKA (B) and EGR1 (C) mRNA expression levels in three individual NHDF exposed to bleomycin (40 mM) or vehicle control (DMSO) for 48 h. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001, n.s. not significant. |
About Function
| Enhancer function : | -- |
| Enhancer function experiment: | -- |
| Enhancer function experiment description: |
-- |
About SNP
| SNP ID: | -- |
Upstream Pathway Annotation of TF
Enhancer associated network
The number on yellow line represents the distance between enhancer and
target gene